Key Points
- CEO Jason Lettmann sold 12,311 shares on March 19 at an average price of $2.17 for $26,714.87, reducing his stake by 4.02% to 293,609 shares (about $637,131) per an SEC filing.
- Analysts are mostly positive: five Buy ratings vs. one Sell, a consensus of "Moderate Buy" and an average price target of $4.60, with firms like UBS and Wells Fargo issuing $5–$6 targets.
- ALXO trades near $2.20 with a market cap of $289.5M, reported a $0.42 loss per share last quarter, and carries a negative P/E (analysts forecast about -2.76 EPS for the year); the 1‑year range is $0.40–$2.66.
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) CEO Jason Lettmann sold 12,311 shares of ALX Oncology stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $2.17, for a total value of $26,714.87. Following the completion of the sale, the chief executive officer owned 293,609 shares of the company's stock, valued at approximately $637,131.53. The trade was a 4.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
ALX Oncology Stock Performance
Shares of NASDAQ:ALXO opened at $2.20 on Tuesday. The company has a current ratio of 2.07, a quick ratio of 2.07 and a debt-to-equity ratio of 0.17. ALX Oncology Holdings Inc. has a 1-year low of $0.40 and a 1-year high of $2.66. The stock has a market capitalization of $289.54 million, a P/E ratio of -1.16 and a beta of 0.46. The business has a 50-day moving average price of $1.98 and a two-hundred day moving average price of $1.63.
ALX Oncology (NASDAQ:ALXO - Get Free Report) last issued its earnings results on Monday, March 9th. The company reported ($0.42) earnings per share (EPS) for the quarter. Equities analysts predict that ALX Oncology Holdings Inc. will post -2.76 earnings per share for the current year.
Analysts Set New Price Targets
Several brokerages have commented on ALXO. UBS Group started coverage on shares of ALX Oncology in a research report on Friday, March 6th. They set a "buy" rating and a $6.00 target price for the company. Piper Sandler raised their price target on ALX Oncology from $3.00 to $4.00 and gave the stock an "overweight" rating in a research report on Thursday, February 5th. Wells Fargo & Company started coverage on ALX Oncology in a research note on Thursday, March 19th. They set an "overweight" rating and a $5.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $4.00 price objective on shares of ALX Oncology in a report on Tuesday, March 10th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of ALX Oncology in a report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $4.60.
Check Out Our Latest Report on ALXO
Institutional Trading of ALX Oncology
A number of large investors have recently made changes to their positions in ALXO. Invesco Ltd. bought a new stake in shares of ALX Oncology in the first quarter valued at about $46,000. Ameriprise Financial Inc. acquired a new position in shares of ALX Oncology during the third quarter worth about $1,195,000. Two Sigma Investments LP grew its holdings in shares of ALX Oncology by 26.9% during the third quarter. Two Sigma Investments LP now owns 606,671 shares of the company's stock worth $1,110,000 after buying an additional 128,737 shares in the last quarter. Acadian Asset Management LLC raised its position in ALX Oncology by 16.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company's stock valued at $806,000 after buying an additional 186,883 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in ALX Oncology by 157.2% in the 4th quarter. Renaissance Technologies LLC now owns 423,099 shares of the company's stock valued at $478,000 after buying an additional 258,600 shares during the last quarter. Institutional investors own 97.97% of the company's stock.
ALX Oncology Company Profile
(
Get Free Report)
ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company's mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.
The lead candidate in ALX Oncology's pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
